Pulmonary sarcomatoid carcinoma is a rare type of non-small cell lung cancer, characterized by high invasiveness and heterogeneity. It is insensitive to traditional radiotherapy and chemotherapy, resulting in an extremely poor prognosis. Immunotherapy, as a significant advancement in the field of lung cancer treatment, provides a new direction for patients with driver gene-negative pulmonary sarcomatoid carcinoma and holds promise for improving clinical outcomes. Based on this, this article reviews the latest research progress on the immunotherapy of pulmonary sarcomatoid carcinoma at home and abroad.